Condition: Recurrent Multiple Myeloma · Refractory Multiple Myeloma · Sponsor: Alliance for Clinical Trials in Oncology
This phase I/II trial tests the safety, side effects, best dose, and effectiveness of iberdomide in combination with belantamab mafodotin and dexamethasone in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory). Multiple myeloma is a cancer that affects white blood cells called plasma cells, which are made in the bone marrow and are part of the immune system. Multiple myeloma cells have a protein on their surface called B-cell maturation antigen (BCMA) that allows the cancer cells to survive and grow. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Belantamab mafodotin has been designed to attach to the BCMA protein, which may cause the myeloma cell to become damaged and die. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Iberdomide plus belantamab mafodotin may help slow or stop the growth of cancer in patients with multiple myeloma.
This description comes directly from the study's public registry record.
Monique Hartley-Brown, MD · 857-215-1692 · MoniqueA_Hartley-Brown@dfci.harvard.edu
Destin Carlisle · 773-702-8824 · dcarlisle@bsd.uchicago.edu
Always discuss trial participation with your own doctor first.
| Mary Greeley Medical Center | Ames, Iowa, United States | Recruiting |
| McFarland Clinic - Ames | Ames, Iowa, United States | Recruiting |
| McFarland Clinic - Boone | Boone, Iowa, United States | Suspended |
| McFarland Clinic - Trinity Cancer Center | Fort Dodge, Iowa, United States | Recruiting |
| McFarland Clinic - Jefferson | Jefferson, Iowa, United States | Suspended |
| McFarland Clinic - Marshalltown | Marshalltown, Iowa, United States | Recruiting |
| Tufts Medical Center | Boston, Massachusetts, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Coborn Cancer Center at Saint Cloud Hospital | Saint Cloud, Minnesota, United States | Recruiting |
| Memorial Sloan Kettering Monmouth | Middletown, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Bergen | Montvale, New Jersey, United States | Recruiting |
| Memorial Sloan Kettering Commack | Commack, New York, United States | Recruiting |
+ 30 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06232044